



Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



Editor Profiles: Guest Editors of Special Column on Hot Topic Reviews in Drug (II)




Dr. Wei Wu received his Bachelor's and Master's degrees in Science from the School of Pharmacy at the Second Military Medical University, and earned his Ph.D. from the School of Pharmacy at West China University of Medical Sciences. In 2000, he joined the School of Pharmacy at Fudan University, where he currently serves as a full professor in the Department of Pharmaceutics. He previously held the position of Vice Dean at the School of Pharmacy.

Throughout his career, Dr. Wu has been recognized with several prestigious honors, including the New Century Excellent Teacher award from the Ministry of Education, Shanghai Excellent Discipline Leader, Shanghai Twilight Scholar, Shanghai Excellent Young University Teacher, and the Distinguished Lectureship Award from the Nagai Foundation Tokyo.

He is currently an expert in drug evaluation for the State Drug Administration (SDA), pharmaceutical pricing for the National Development and Reform Commission (NDRC), and veterinary medicine for the Ministry of Agriculture. Dr. Wu holds key editorial roles in several leading journals: he serves as Vice Editor-in-Chief for *Acta Pharmaceutica Sinica B*, Associate Editor for *Chinese Chemical Letters*, *Journal of Drug Delivery Science and Technology*, and *Journal of Biomedical Nanotechnology* (2019–2023), and Section Editor-in-Chief for *Pharmaceutics*. He is also a member of the editorial boards of numerous international journals, including *AAPS PharmSciTech*, *Archives of Pharmacal Research*, *Asian Journal of Pharmaceutical Sciences*, *Current Drug Delivery*, *Drug Delivery*, *Drug Delivery Letters*, *Heliyon*, *International Journal of Pharmaceutics*, *Pharmaceutical Research*, and *Processes*. In addition, he has served as an *ad hoc* guest editor for several journals, such as *Advanced Drug Delivery Reviews*, *Asian Journal of Pharmaceutical Sciences*, and *International Journal of Pharmaceutics*.

His research interests encompass the biological fate of drug carrier systems, oral nanoparticulate drug delivery systems, novel

dosage forms and pharmaceutical technologies, as well as skin healthcare and disease treatment. He has authored over 300 peer-reviewed articles in the fields of pharmaceutics and nanomedicine.



Dr. Wei He is a Professor at the College of Pharmaceutical Science China Pharmaceutical University. His current research interests mainly include drug delivery and pharmaceutical science. He is listed on the editorial boards of several academic journals, including *Chin Chem Lett*, *Acta Pharm Sin*, and *Pharmaceutics*. He works as a guest editor for *Acta Pharm Sin B* and *Adv Drug Deliv Rev*. He has published over

100 peer-reviewed papers and is listed as one of Stanford's top 2% most highly cited scientists 2022, 2024 and 2025.



Dr. Zongmin Zhao is an Assistant Professor in the Department of Pharmaceutical Sciences at University of Illinois Chicago and a Full Member of the University of Illinois Cancer Center. Dr. Zhao received his Ph.D. in Biological Systems Engineering from Virginia Tech and completed his post-doctoral training at Harvard University. His group focuses on integrating cellular engineering, biomaterials, and immunology to develop "living carriers" and "living drugs"

for targeted drug delivery and immunotherapy. His work has been published in *Cell*, *Nature Biomedical Engineering*, *Nature Communications*, *Science Advances*, and other leading journals. Dr. Zhao is a recipient of the NIH Maximizing Investigators' Research Award (MIRA) and multiple Emerging Investigator awards, and currently serves as Associate Editor of *Bioengineering & Translational Medicine*.

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2026.03.049>

2211-3835 © 2026 Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).